These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26513691)

  • 1. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
    Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
    Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation.
    Sharma P; Mahen R; Rossmann M; Stokes JE; Hardwick B; Huggins DJ; Emery A; Kunciw DL; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR
    Sci Rep; 2019 Nov; 9(1):15930. PubMed ID: 31685831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A; Berg T
    Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
    Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L
    J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian polo-like kinase 1-dependent regulation of the PBIP1-CENP-Q complex at kinetochores.
    Kang YH; Park CH; Kim TS; Soung NK; Bang JK; Kim BY; Park JE; Lee KS
    J Biol Chem; 2011 Jun; 286(22):19744-57. PubMed ID: 21454580
    [TBL] [Abstract][Full Text] [Related]  

  • 12.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition.
    Watanabe N; Sekine T; Takagi M; Iwasaki J; Imamoto N; Kawasaki H; Osada H
    J Biol Chem; 2009 Jan; 284(4):2344-53. PubMed ID: 19033445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
    Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
    Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
    McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
    Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.